USOD PUBLISHERS
United Scientific Open Discovery

Journal of Surgical Outcomes and Innovation
Volume 2 | Issue 2

Review Article

Beyond Antioxidant Protection: Palm-Derived γ-Tocotrienol, Mitochondrial Bioenergetics, and the Translational Challenge of Preventing Perioperative Acute Kidney Injury

Loso Judijanto

IPOSS Jakarta, Indonesia

***Corresponding author:** Loso Judijanto, IPOSS Jakarta, Indonesia. ORCID: https://orcid.org/0009-0007-7766-0647.

Citation: Loso Judijanto (2026) Beyond Antioxidant Protection: Palm-Derived γ-Tocotrienol, Mitochondrial Bioenergetics, and the Translational Challenge of Preventing Perioperative Acute Kidney Injury. J of Sur Out & Inno 2(2), 1-11.

Received Date: October 16, 2026
Accepted Date: October 28, 2026
Published Date: October 30, 2026

Abstract

Perioperative acute kidney injury remains a clinically consequential complication of cardiac, vascular, and transplantation procedures, and available preventive strategies do not eliminate residual risk. This qualitative literature review evaluates whether palm-derived γ-tocotrienol could contribute to renal protection through preservation of mitochondrial bioenergetics and attenuation of ischemia–reperfusion-related injury. Peer-reviewed research published between 2020 and 2026 was interpreted across renal mitochondrial biology, experimental tocotrienol pharmacology, perioperative clinical care, and transplantation. A pivotal mouse study associates γ-tocotrienol pretreatment with preserved mitochondrial respiratory activity, adenosine triphosphate availability, tubular morphology, and selected functional outcomes after renal ischemia. Mechanistic connections to reactive oxygen species, inflammatory signalling, mitochondrial dynamics, and regulated cell death are biologically plausible but incompletely established for this specific compound. Crucially, experimental exposure cannot be equated with human perioperative efficacy. Variable oral bioavailability, uncertain formulation-specific dosing, possible medication interactions, surgical bleeding concerns, and the mismatch between experimental ischemia models and complex operations are unresolved barriers. We propose a staged translational program comprising independent replication, human pharmacokinetic and safety evaluation, biomarker-enriched feasibility studies, and adequately powered trials using validated acute kidney injury definitions and patient-centered outcomes. γ-Tocotrienol is a hypothesis-generating cytoprotective candidate, not an established preventive treatment. γ

Keywords: Perioperative Acute Kidney Injury, γ-Tocotrienol, Palm-Derived Vitamin E, Mitochondrial Bioenergetics, Ischemia–Reperfusion Injury, Cardiac Surgery, Kidney Transplantation, Oxidative Stress, Tubular Epithelial Injury, Translational Research

JEL Classification: I10, I12, I18, O33, Q16

Introduction

Perioperative acute kidney injury as an unresolved surgical problem

Recent perioperative reviews emphasize that changes in creatinine and urine output identify kidney dysfunction later than some injury processes and can be influenced by hemodilution, fluid balance, and other clinical factors. This diagnostic lag complicates estimates of intervention timing and underscores the need to pair KDIGO-defined outcomes with appropriately selected structural or stress biomarkers, without claiming that biomarker movement alone constitutes clinical recovery (Douville et al., 2025, Zuzda et al., 2026).

Acute kidney injury after surgery is not merely an incidental rise in serum creatinine. It may indicate an abrupt failure of renal filtration, tubular transport, and the organ's capacity to maintain systemic fluid and metabolic balance. Postoperative acute kidney injury (PO-AKI) is commonly defined using Kidney Disease: Improving Global Outcomes (KDIGO) criteria when the qualifying injury occurs within seven days of surgery. Its clinical consequences encompass prolonged intensive care, greater resource consumption, short-term complications, and heightened risk of subsequent chronic kidney disease. These associations warrant attention to the mechanisms of tissue injury as well as to conventional functional indicators, particularly among patients undergoing procedures characterized by hypotension, embolic insults, extracorporeal circulation, or temporary interruption of blood flow (Prowle et al., 2021, Brown et al., 2023a).

Cardiac surgery illustrates the difficulty of protecting a vulnerable kidney despite modern perioperative care. Cardiopulmonary bypass can create hemodilution, altered pulsatility, inflammatory activation, hemolysis, and fluctuations in oxygen delivery, while pre-existing chronic kidney disease and cardiac dysfunction increase susceptibility. Contemporary reviews identify a substantial postoperative AKI burden and emphasize that a broad range of pharmacological prevention strategies have failed to produce convincing, generalizable benefit. Interventions directed at perfusion and renal functional reserve have generated encouraging signals, but effectiveness varies by population, design, and endpoint. A useful investigative framework should therefore distinguish established supportive care, interventions supported by randomized clinical evidence, and mechanisms that remain experimental rather than combining them into an undifferentiated narrative of renal protection (Jacob and Leaf, 2025, Kamla et al., 2025, Scurt et al., 2024).

Why a mitochondrial and nutraceutical hypothesis merits examination

The renal proximal tubule depends heavily on oxidative

metabolism to fuel sodium transport, solute reabsorption, and the maintenance of epithelial polarity. When oxygen supply falls, electron transport is interrupted, the proton-motive force declines, and ATP production becomes inadequate for transport demands. Reperfusion restores oxygen but can also produce excessive mitochondrial reactive oxygen species, calcium imbalance, membrane injury, and inflammatory signaling. These events make mitochondria attractive candidate targets, although mitochondrial protection is not equivalent to protecting the kidney at the patient level. An agent that improves isolated respiratory-chain measurements may not avert congestion, microembolization, prolonged hypotension, nephrotoxin exposure, or other causes of postoperative AKI. Accordingly, mitochondria-centered interventions require both mechanistic specificity and clinical validation (Tang et al., 2021, Pabla and Bajwa, 2022, Pan and Zhu, 2026).

Palm-derived γ-tocotrienol (γ-tocotrienol) is particularly relevant because it belongs to the unsaturated vitamin E family and has experimental antioxidant and cytoprotective activities. A key mouse study administered γ-tocotrienol before bilateral renal ischemia and found preservation of several mitochondrial respiratory-chain and energy-related measures, improved tubular morphology, and more favorable creatinine recovery. This observation creates a plausible mechanistic point of departure rather than a therapeutic recommendation. It also differentiates the present review from investigations of tocotrienols in diabetic kidney disease: the central question here concerns acute perioperative hypoperfusion, reperfusion stress, and tubular mitochondrial recovery, not prolonged metabolic and microvascular injury. The fundamental translational issue is whether experimental protection can be reproduced safely at clinically relevant exposures (Nowak and Megyesi, 2021, Zainal et al., 2022).

Review purpose and contribution

The purpose of this qualitative review is to evaluate how γ-tocotrienol might influence the biological processes implicated in perioperative kidney injury, to compare relevant surgical environments, and to identify the evidence required for responsible clinical development. The analysis considers functional kidney measurements alongside markers of cellular stress, explores delivery and dose uncertainties, and situates any proposed intervention within contemporary consensus-guided perioperative practice. It expressly avoids treating animal experiments as direct evidence of postoperative benefit in humans. A further contribution is the explicit separation of mechanistic efficacy, exposure feasibility, safety, and patient-centered outcomes, which should prevent otherwise promising bioactive compounds from moving prematurely into unsupervised use around major operations (Oosterom-Eijmael et al., 2026, Kulthinee et al., 2024, Ostermann et al., 2020).

Literature Review: Conceptual and Theoretical Foundations

Oxygen mismatch, ischemia, and tubular vulnerability

Perioperative renal injury often begins with an imbalance between renal oxygen delivery and the metabolic costs of tubular transport. Mean arterial pressure is relevant, but it does not capture the complete renal circulation: cardiac output, venous pressure, hemoglobin concentration, perfusion distribution, autoregulatory reserve, and oxygen extraction also matter. During major surgery, hypotension may coexist with anemia, fluid shifts, vasoconstriction, or bypass-associated disturbances. Observational associations between prolonged intraoperative hypotension and AKI strengthen the physiological rationale for perfusion optimization, while randomized studies of oxygen delivery-guided perfusion in cardiac surgery show that modifiable systemic determinants can affect postoperative AKI occurrence. These findings establish why cytoprotection should be investigated as an adjunct to, not a substitute for, maintaining adequate tissue perfusion (Penev et al., 2024, Mukaida et al., 2023).

The proximal tubular epithelium is vulnerable to ischemia because high transport demand is coupled to abundant mitochondria and limited glycolytic reserve. ATP depletion compromises basolateral sodium-potassium ATPase activity and tight junction organization, disrupts brush-border structures, and changes transepithelial transport. Damaged cells may detach, obstruct tubular lumina, or engage in stress signaling that influences adjacent endothelial, immune, and interstitial compartments. However, a reduction in glomerular filtration may arise from multiple interacting mechanisms even when frank tubular necrosis is limited. Modern descriptions of epithelial cell states and glomerulotubular communication argue against a simple one-way model in which ischemia produces necrosis and necrosis alone explains all functional deterioration (Hinze et al., 2024, Fogo and Harris, 2025).

Electron transport, redox imbalance, and mitochondrial permeability

Mitochondria convert reducing equivalents generated by oxidative metabolism into an electrochemical gradient across the inner membrane. Complexes I, III, and IV support proton translocation, while ATP synthase uses the gradient for phosphorylation of ADP. During ischemia, substrate accumulation, reduced respiratory flux, and ionic imbalance disturb this coupling, during reperfusion, reoxygenation may increase electron leakage and reactive oxygen species generation. Experimental investigations implicate AMPK signaling and mitochondrial DNA maintenance in the severity of ischemic AKI, highlighting the interdependence of respiratory function, energy sensing, and inflammation. Importantly, reactive oxygen species are not invariably harmful: physiological redox signals are required for adaptation, so the objective should be restoration of redox regulation rather than indiscriminate elimination of every oxidative signal (Ma et al., 2022, Zhao et al., 2021).

Figure 1 maps the proposed connections between surgical stressors, mitochondrial injury, tubular dysfunction, and the site at which experimental γ-tocotrienol might intervene. It deliberately distinguishes the experimentally observed preclinical signal from the absence of validated human perioperative prevention (Nowak and Megyesi, 2021, Tang et al., 2021).




Figure 1: A hypothesis-driven mitochondrial–tubular framework for perioperative AKI

The upper sequence depicts pathways that may coexist rather than a single linear mechanism: perfusion disturbances and reperfusion can change respiratory-chain performance, redox homeostasis, epithelial viability, and inflammatory tone. The dashed arrow indicates the proposed—but not clinically proven—intervention point for γ-tocotrienol. The diagram therefore must not be interpreted as evidence that administration prevents postoperative AKI in patients.

Mitochondrial dysfunction extends beyond the electron transport chain. Fission, fusion, and mitophagy determine whether damaged organelles are segregated and removed or remain to propagate injury. Mitochondrial biogenesis supports the renewal of respiratory capacity during repair, whereas excessive fragmentation or defective clearance may favor prolonged inflammation. Kidney-injury reviews describe alterations in membrane potential, reactive oxygen species, mitochondrial permeability transition, and the coordination of these quality-control processes. This integrated picture argues against interpreting a single ATP measurement as proof of complete mitochondrial protection. A stronger experimental claim would require convergent assays for respiratory flux, complex activities, mitochondrial morphology, quality-control dynamics, tissue energy content, and preservation of epithelial function over several recovery intervals (Yao et al., 2024, Li et al., 2025).

Mitophagy can be beneficial when it removes irreversibly injured mitochondria, but both insufficient and excessive mitochondrial clearance may perturb tissue homeostasis. Pathways involving PINK1/Parkin and receptor-mediated mitophagy interact with energy sensors, sirtuins, and transcriptional regulators of mitochondrial biogenesis. Reviews of acute kidney injury emphasize that injury and repair cannot be captured by static organelle abundance or one terminal observation. For γ-tocotrienol, this implies the need for temporal mechanistic experiments rather than simply demonstrating lower oxidative biomarkers at an arbitrary postoperative time. If respiratory recovery reflects improved removal or replacement of damaged organelles, future studies should establish the mediator experimentally through targeted pharmacological or genetic perturbations (Wang et al., 2020, Su et al., 2023, Perico et al., 2024).

Oxidative injury, inflammation, and regulated cell death

Acute kidney injury involves coordinated cellular responses that can be protective at one stage and damaging at another. Endothelial perturbation, neutrophil recruitment, monocyte or macrophage activation, and lymphocyte responses interact with injured tubules to influence injury severity and subsequent repair. Innate immune pathways can amplify oxidative stress through cytokines, chemokines, and extracellular traps, while some immune populations are required for debris clearance and regeneration. Translational pharmacology must therefore consider the timing and direction of immune modulation. A compound that broadly reduces inflammatory signaling may improve an early injury marker yet disrupt later host defense or tissue recovery, particularly among immunosuppressed transplant recipients or patients exposed to invasive devices and prolonged hospitalization (Lee et al., 2024, Meng et al., 2025).

Ferroptosis, a regulated cell-death process linked to iron-dependent phospholipid peroxidation, has emerged as an important experimental axis in ischemic kidney injury. Work on maladaptive renal repair suggests that sustained ferroptotic stress can promote inflammatory proximal tubular states and fibrosis. Other studies show that modifying the SLC7A11/glutathione-dependent defense system can change injury severity in animal or cellular models. These findings are relevant to tocotrienols because lipid-phase antioxidants might intercept peroxidative chain reactions. Nevertheless, the inference remains mechanistic: it has not been established that the beneficial kidney outcomes observed after γ-tocotrienol pretreatment are mediated specifically through ferroptosis inhibition, and vitamin E family compounds can have context-dependent effects that should not be generalized across models (Ide et al., 2021, Thapa et al., 2022, Ma et al., 2023).

Pyroptosis, oxidative signaling, and regulated necrosis constitute further routes by which early mitochondrial disturbance becomes sustained kidney inflammation. Studies examining gasdermin-mediated membrane injury and reactive-oxygen-species-dependent ferroptosis indicate that multiple death pathways coexist rather than forming a single linear sequence. NRF2-directed antioxidant responses also interact with inflammatory and fibrotic processes, making cellular stress biology a network rather than an isolated molecular target. These pathways should enter the proposed causal model as candidates for testing, not as γ-tocotrienol effects already demonstrated in surgical patients. A robust translational study would document pathway engagement with validated assays and distinguish whether improvements reflect direct mitochondrial stabilization or secondary consequences of less tissue injury (Ma et al., 2024, Pan et al., 2023, Ng et al., 2025).

What gamma-tocotrienol is, and what it is not

Tocotrienols and tocopherols share a chromanol head group but differ in their hydrophobic side chains, tocotrienols contain three unsaturated bonds. The alpha, beta, gamma, and delta isoforms also differ in methyl substitution, potentially influencing membrane

behavior, metabolism, and biological responses. γ-Tocotrienol should not be treated as equivalent to alpha-tocopherol, a generic vitamin E supplement, annatto-derived delta-tocotrienol, or an unspecified palm tocotrienol-rich fraction. Interventions derived from palm oil may contain several tocotrienols and tocopherols, and their relative compositions can alter pharmacokinetics and potential effects. Chemically authenticated material, quantified purity, oxidation stability, and analytically characterized excipients are therefore prerequisites for credible replication of the renal ischemia study (Szewczyk et al., 2021, Ranasinghe et al., 2022).

Although tocotrienols exhibit antioxidant and anti-inflammatory activities in varied laboratory settings, oral bioavailability and tissue exposure can be variable. Human pharmacokinetic studies and formulation reviews emphasize poor aqueous solubility, dependence on absorption conditions, rapid elimination, and differences among individual isoforms and products. Perioperative patients introduce additional uncertainties: fasting, altered gastrointestinal motility, vasopressor use, impaired splanchnic perfusion, postoperative nausea, and temporary inability to swallow capsules may all complicate oral dosing. Since the most relevant renal experiment used a defined pretreatment schedule in mice, it is essential to avoid translating its milligram-per-kilogram quantity directly into a prescribed human dose. Formulation-specific exposure data must precede selection of a clinically credible prevention schedule (Zainal et al., 2022, Sharif et al., 2023, Ooi et al., 2026).

Methods: Qualitative Literature Review

Interpretive design and evidence boundaries

This manuscript uses a qualitative literature review design with theory-informed, critical thematic synthesis. The objective is to interpret relationships among perioperative physiology, renal mitochondrial injury, γ-tocotrienol pharmacology, and translational development rather than to estimate a pooled treatment effect. Literature was identified through topic-focused searches of PubMed/MEDLINE, biomedical publisher platforms, and linked journal bibliographies, prioritizing peer-reviewed publications from 2020 through October 2026. Search concepts included perioperative AKI, cardiac surgery-associated AKI, renal ischemia-reperfusion, mitochondria, respiratory complexes, ATP, lipid peroxidation, inflammation, ferroptosis, biomarkers, kidney transplantation, tocotrienols, and pharmacokinetics. The search was iterative and purposive, neither exhaustive retrieval nor PRISMA-style study flow is claimed (Prowle et al., 2021, Tang et al., 2021).

Appraisal and integration strategy

Source interpretation privileged direct experimental studies for compound-specific claims, randomized trials and consensus guidance for existing clinical interventions, and recent mechanistic reviews for explanatory context. The critical appraisal distinguished study species, intervention identity, dosage, route, timing, comparator, organ-injury model, outcome measurement, and strength of causal inference. Human trials evaluating amino acids, biomarker-guided care, or organ preservation were not considered evidence of tocotrienol efficacy, they served as clinical comparators demonstrating what credible endpoints and implementation safeguards require. Themes were synthesized through structured narrative comparison and the explicit identification of agreement, inconsistency, transferability limits, and unresolved questions. Because no formal systematic screening or quantitative risk-of-bias scoring was performed, the review should not be interpreted as an unbiased inventory of all published research (Ostermann et al., 2020, Brown et al., 2023a).

Analytical categories

Five cross-cutting categories guided extraction and interpretation: mitochondrial bioenergetics and quality control, oxidative and inflammatory signaling, procedure-specific renal injury mechanisms, pharmacological feasibility and perioperative safety, and the hierarchy of molecular, organ-level, and patient-centered outcomes. These categories were deliberately linked rather than treated as independent silos because a compound can have measurable biochemical activity yet fail to reach renal tissue, fail to modify clinically relevant injury pathways, or introduce perioperative hazards. The resulting narrative is hypothesis-generating. It identifies the conditions under which a more formal evidence synthesis, reproducibility program, and eventual clinical trial could become justified without misrepresenting a qualitative interpretation as conclusive clinical evidence (Pan and Zhu, 2026, Hinze et al., 2024).

Results: Thematic Findings

A focused experimental signal: mitochondrial respiratory protection

The most direct compound-specific observation comes from Nowak and Megyesi's mouse renal ischemia-reperfusion experiment. γ-Tocotrienol was administered at 200 mg/kg 12 h before bilateral renal ischemia, and several endpoints were followed during reperfusion. Pretreatment lessened depression of state 3 mitochondrial respiration, preserved activities of selected electron-transport complexes, mitigated loss of ATP synthase activity and renal cortical ATP, and improved morphological measures of injury and repair. Plasma creatinine trajectories also recovered more favorably in treated mice. Reported survival was numerically higher in treated animals, but the design and sample size do not support extrapolation to perioperative human survival benefits. These findings provide biological plausibility and an investigational rationale, not evidence of a standardized clinical prophylactic effect (Nowak and Megyesi, 2021).

The mechanistic findings deserve a more discriminating interpretation than the general statement that γ-tocotrienol is an antioxidant. Preservation of complex I and III activities, ATP synthase function, and energy content points toward an association with respiratory-chain resilience. Yet it does not demonstrate direct physical binding to individual complexes, nor exclude upstream effects on oxidative stress, inflammation, or cellular composition. Independent studies implicating AMPK phosphorylation and mitochondrial DNA maintenance show that similar functional endpoints can improve through different mechanisms. Consequently, the appropriate causal proposition is that γ-tocotrienol pretreatment may interrupt a network of ischemia-associated bioenergetic disturbances. Direct target engagement, dose-response relationships, and pathway-specific mediation remain open research questions (Nowak and Megyesi, 2021, Ma et al., 2022, Zhao et al., 2021).

Mitochondrial dynamics and oxidative stress: convergence without proof of equivalence

Independent renal ischemia studies show that mitochondrial fission-fusion balance can be changed by inflammatory or purinergic signaling, with resulting differences in tissue injury. Evidence linking neutrophil extracellular traps to altered mitochondrial dynamics reinforces the possibility that preserving mitochondria requires coordinated vascular and immunological responses. Recent reviews emphasize the importance of mitophagy and the removal of damaged organelles for recovery from acute injury. These findings support a multilayer hypothesis for γ-tocotrienol but cannot be merged into a single established pathway. Specifically, no credible inference follows that a tocotrienol regimen reproduces

the effects of genetic P2RX1 inhibition or any individual mitophagy intervention merely because all approaches touch mitochondrial endpoints (Zhuang et al., 2021, Yao et al., 2024, Su et al., 2023).

Oxidative stress and lipid peroxidation form a second mechanistic convergence point. NRF2-related defense systems, lipid peroxide detoxification, mitochondrial membrane stability, and inflammatory cell-death pathways can interact during reperfusion. Severe peroxidative stress can promote maladaptive epithelial phenotypes rather than ending when blood flow resumes. γ-Tocotrienol's lipid-phase chemistry suggests a plausible opportunity to affect these processes, but the observation that a compound belongs to the vitamin E family does not verify that it suppresses renal ferroptosis in vivo. Mechanistic follow-up should measure oxidized phospholipids, glutathione status, GPX4 activity, iron handling, and cell-specific injury states together with mitochondrial respiration, while using appropriate controls to distinguish antioxidant chemistry from broader biological effects (Ng et al., 2025, Ide et al., 2021, Ma et al., 2024).

Evidence relating inflammatory signaling to tubular recovery

The inflammatory component of ischemic AKI includes leukocyte recruitment, endothelial activation, innate immune sensors, and tubular stress signals that influence the distribution and duration of renal injury. Contemporary work identifies both harmful and reparative roles for immune cells and warns against interpreting inflammation as uniformly undesirable. Studies of gasdermin-mediated pyroptosis provide examples of how organelle dysfunction can amplify inflammatory cell death, whereas renal repair may require carefully timed immune participation. For γ-tocotrienol, inflammatory endpoints should therefore be measured alongside infection susceptibility, wound recovery, and treatment context. A favorable cytokine trajectory alone would not justify clinical use if it were accompanied by impaired healing or increased postoperative infection risk (Lee et al., 2024, Meng et al., 2025, Ma et al., 2024).

Functional recovery after an ischemic insult depends on the restoration of viable epithelial states, endothelial stability, and coordinated intercellular communication. Single-cell and kidney injury analyses suggest that proximal tubule cells can recover from transient damage or persist in maladaptive inflammatory states associated with fibrosis. These trajectories underscore why a short-term serum creatinine improvement may not be sufficient to infer durable nephroprotection. Investigators should assess tubular regeneration, sustained filtration, albuminuria where appropriate, and longer-term kidney health. The crucial translational hypothesis is not simply that cells survive initial oxidative stress, it is that cellular preservation improves the probability of structurally and functionally meaningful repair, without increasing delayed injury or persistent inflammation (Ide et al., 2021, Hinze et al., 2024, Fogo and Harris, 2025).

Cardiac surgery: the clearest initial trial platform

The evidence base for kidney-protective background care is stronger than that for experimental nutraceuticals. A multi-society cardiac surgery guideline recommends avoiding hyperthermic cardiopulmonary bypass and employing goal-directed oxygen-delivery strategies, while recognizing the role of KDIGO-based care for high-risk patients. These interventions must be documented and maintained in both arms of any future γ-tocotrienol trial so that any incremental effect is measured against credible contemporary practice (Brown et al., 2023a, Brown et al., 2023b).

Cardiac surgery represents an attractive clinical setting because kidney injury may be anticipated, risk factors can be assessed before surgery, and serial perioperative samples are feasible. However, bypass-associated hemolysis, systemic inflammation, ischemic exposure, venous congestion, and embolic burden complicate attribution of outcomes to a single mitochondrial mechanism. Differences in patient sex, preoperative kidney health, cardiac function, and procedural complexity can produce substantial heterogeneity. A γ-tocotrienol study would need to stratify these factors and establish exposure before predictable ischemic stress. It should also preserve conventional kidney care, since biological supplementation cannot correct poor oxygen delivery or major circulatory insufficiency. Any observed clinical signal must be evaluated against strong background supportive management rather than against an avoidably weak standard-care comparator (Scurt et al., 2024, Kamla et al., 2025, Kulthinee et al., 2024).

Evidence from interventions other than tocotrienols provides useful design lessons. In a large multinational randomized trial, perioperative intravenous amino acids reduced creatinine-defined AKI after cardiac surgery, whereas a randomized trial of oxygen delivery-guided bypass perfusion identified a protective signal in its population. Biomarker-guided application of a KDIGO-derived bundle has also demonstrated feasibility and improvement in some measures of AKI severity. These findings do not establish a universal pharmacological prevention strategy, and they do not demonstrate γ-tocotrienol efficacy. They show, instead, that prospective risk definition, treatment fidelity, physiologic optimization, and meaningful comparison groups are indispensable when testing a new preventive hypothesis in high-risk surgical patients (Landoni et al., 2024, Mukaida et al., 2023, Zarbock et al., 2021).

The clinical development landscape remains cautionary. Teprasiran, a short interfering RNA approach, illustrates the danger of extrapolating from a promising earlier-stage randomized study: despite initial reductions in early AKI, a subsequent larger study did not establish the anticipated clinical efficacy and was terminated prematurely for futility. Reviews emphasize that many historically investigated preventive agents have produced neutral results or unresolved questions. For γ-tocotrienol, this translates into a requirement for rigorous replication and independent development rather than an assumption that successful antioxidant biology will overcome clinical heterogeneity. Early trial planning should consider whether participants already receive kidney protective bundles, which may lower event rates and make small additional benefits more difficult to detect statistically (Thielmann et al., 2021, Scurt et al., 2024, Jacob and Leaf, 2025, Losiggio et al., 2025).

Vascular operations and kidney transplantation: related, not interchangeable

Complex vascular surgery may involve aortic cross-clamping, temporary renal artery flow interruption, blood loss, embolization, contrast exposure, and postoperative perfusion instability. These injuries share the biology of ischemia-reperfusion with controlled mouse experiments, yet their intensity and anatomical distribution vary. Emergency procedures pose particular challenges for pharmacological preconditioning because meaningful treatment time before ischemia may not exist. Furthermore, variable operative exposures complicate interpretation of early creatinine changes. Elective vascular surgery may offer a narrow feasibility window for a verified formulation, but trials should specify whether the intervention is intended for preconditioning, early reperfusion treatment, or postoperative damage limitation, those are distinct pharmacological strategies with different evidentiary requirements (Penev et al., 2024, Prowle et al., 2021).

Kidney transplantation presents a distinctive preservation problem. The organ experiences warm and cold ischemia, procurement-associated insults, and reperfusion in a recipient with variable hemodynamics and immune status. Delayed graft function is commonly operationalized as a requirement for dialysis within the first week, although definitions and center practices can differ. The relevant intervention might be delivered to the donor, the recipient, or a controlled perfusion circuit containing the graft. Each route introduces different exposure, regulatory, and toxicity considerations. Oral γ-tocotrienol supplementation of recipients cannot be assumed to reproduce direct renal exposure in a mouse pretreatment model, while ex vivo use would require demonstration of compatibility with preservation solutions and graft perfusion systems (Ponticelli et al., 2022, Barbosa et al., 2023, Abou Taka et al., 2023).

Organ-preservation trials illustrate the importance of testing rather than presuming that a biologically attractive intervention improves outcomes. A randomized trial of a brief normothermic perfusion period in donation-after-circulatory-death kidneys did not reduce delayed graft function compared with static cold storage, despite strong mechanistic interest in metabolic recovery. Other studies have compared hypothermia or machine perfusion during donor management, while evidence syntheses identify potential benefits of certain perfusion strategies across settings. These outcomes are heterogeneous and intervention-specific. An ex vivo tocotrienol approach therefore requires preclinical assessments of solubility, concentration, circuit adsorption, oxygenation, tissue penetration, graft function, and recipients' safety before advancing toward any randomized transplant comparison (Hosgood et al., 2023, Malinoski et al., 2023, Hasjim et al., 2024).

Pharmacokinetics, formulation, and safety remain decisive gaps

Available human pharmacokinetic work makes clear that a nominal ingested dose is not a reliable surrogate for renal tissue exposure. Mixed tocotrienol preparations vary in their isoform composition, while absorption of lipid-soluble compounds depends on formulation and physiological state. Self-emulsifying delivery systems can enhance tocotrienol solubility and systemic absorption in selected contexts, although the extent of improvement depends on the product and study population. A surgical research formulation should therefore be investigated as a pharmaceutical-like intervention with batch identity, bioanalytical measurement, validated stability, and predefined pharmacokinetic acceptance criteria. The absence of a standardized perioperative γ-tocotrienol formulation is a major reason mechanistic plausibility cannot yet be converted into a routine clinical recommendation (Sharif et al., 2023, Lee et al., 2022, Mohamad, 2023).

Perioperative safety is a separate and equally important hurdle. Tocotrienols may be well tolerated in dietary contexts, but this does not establish safety at higher investigational doses near cardiopulmonary bypass, major vascular reconstruction, transplantation, or invasive regional anesthesia. Effects on hemostasis, platelet function, anticoagulant or antiplatelet medications, anesthetic interactions, hepatic metabolism, and impaired gastrointestinal absorption deserve explicit evaluation. A first-in-surgery study would need an independently reviewed adverse-event framework and prespecified stopping criteria. Because formulations may contain additional bioactive molecules or excipients, studies must document their potential effects instead of attributing all observed responses to γ-tocotrienol itself (Ooi et al., 2026, Ranasinghe et al., 2022, Szewczyk et al., 2021).

Discussion and Critical Analysis

Biological plausibility is not evidence of perioperative clinical effectiveness

The integrated literature supports a coherent hypothesis: γ-tocotrienol given before ischemia may help preserve mitochondrial respiratory activity and energy status, thereby reducing tubular injury and improving the conditions for recovery. However, the research has not established that such an effect will occur in humans receiving realistic formulations under real surgical conditions. The causal chain contains multiple vulnerable links, including delivery to the kidney, exposure at the correct time, engagement of the relevant mitochondrial pathway, measurable organ protection, and improvement in patient outcomes. A positive experimental result addresses only some of these links. Preserving that distinction is necessary both for scientific credibility and for protecting patients from premature claims surrounding a commercially available bioactive ingredient (Nowak and Megyesi, 2021, Tang et al., 2021, Pan and Zhu, 2026).

A further mechanistic problem is whether γ-tocotrienol principally prevents mitochondrial injury or instead reduces upstream causes of that injury. Respiratory-chain preservation might result from direct membrane antioxidant activity, altered cytokine production, changes in renal microcirculation, shifts in energetic regulation, or improved survival of intrinsically healthier tubular cells. Those explanations are experimentally distinguishable. Future studies should combine purified mitochondrial assays with intact-cell experiments, live or ex vivo organ systems, and pharmacological or genetic pathway perturbation. For example, an observed improvement in ATP content would become more informative if paired with oxygen consumption, membrane-potential measurements, complex-specific assays, and evidence that pathway manipulation weakens or abolishes the treatment response (Ma et al., 2022, Zhao et al., 2021, Zhuang et al., 2021).

Oxidative stress requires precision rather than a generic antioxidant claim

The common formulation that all ischemia-reperfusion injury results from reactive oxygen species is too reductive. Oxidants can damage membranes and proteins, but redox signals also regulate survival responses and immune communication. Similarly, ferroptosis comprises iron-dependent phospholipid peroxide accumulation and failure of specific defense mechanisms, not simply an elevation of a nonspecific oxidant assay. To claim that γ-tocotrienol prevents ferroptosis, researchers should show changes in ferroptosis-specific molecular and morphological markers, establish time-dependent association with renal outcomes, and employ rescue or loss-of-function approaches. A general antioxidant endpoint might support the rationale but cannot substitute for pathway specificity, particularly when many other interdependent injury processes operate during complex surgery (Ide et al., 2021, Ng et al., 2025, Thapa et al., 2022).

Experimental compounds acting through SLC7A11-related pathways or regulators of ROS-dependent ferroptosis illustrate how interference with cell-death signaling can influence kidney injury, while gasdermin-associated pyroptosis studies underline the simultaneous relevance of inflammatory cell-death mechanisms. Those studies should be used as mechanistic context, not as surrogate demonstrations of γ-tocotrienol treatment effects. Researchers need to avoid the post hoc practice of selecting a pathway because it fits an observed improvement. A credible design should specify the primary proposed pathway in advance, include measures of plausible alternatives, and report discordant findings, including cases in which mitochondrial metrics improve without accompanying histological or kidney-functional benefit (Ma et al., 2023, Pan et al., 2023, Ma et al., 2024).

Clinical positioning alongside proven supportive interventions

In the PROTECTION trial, perioperative intravenous amino acids reduced creatinine-defined AKI from 31.7% in the placebo group to 26.9% in the intervention group, although kidney replacement therapy was infrequent in both groups. This is evidence for that specific amino-acid intervention rather than for γ-tocotrienol, and the distinction should be made whenever renal biomarkers or experimental protective mechanisms are compared with clinical preventive strategies (Landoni et al., 2024, Douville et al., 2025).

No mechanistic supplement can replace assessment of baseline kidney health, reduction of avoidable nephrotoxins, attention to perfusion, individualized fluid therapy, and early recognition of postoperative AKI. Consensus recommendations emphasize patient-specific risk assessment, goal-directed hemodynamic management in selected high-risk patients, avoidance of hypotension, and postoperative kidney-health follow-up. These components represent the ethical background against which a future γ-tocotrienol intervention must be tested. An adjunctive design would be more clinically credible than a head-to-head comparison against absent supportive care. Furthermore, an intervention may be considered promising even if it influences certain biomarkers before creatinine, but without patient-centered clinical improvement its role would remain investigational rather than established (Brown et al., 2023a, Prowle et al., 2021, Scurt et al., 2024).

Contemporary clinical research supplies practical examples of meaningful trial organization. Amino-acid infusion and biomarker-guided kidney-care bundles are not mechanistically equivalent to tocotrienols, yet their trials illuminate the advantages of prespecified populations, clinically coherent intervention windows, and consistent AKI definitions. Biomarkers such as urinary TIMP-2 and IGFBP7 can identify tubular stress before a large creatinine change, while NGAL and other analytes provide different types of injury information. Still, biomarker responsiveness is not by itself proof that a strategy prevents severe AKI, dialysis, persistent dysfunction, or death. γ-Tocotrienol trials would need a hierarchy of endpoints so that a mechanistic signal cannot displace a neutral clinical outcome in the final interpretation (Landoni et al., 2024, Zarbock et al., 2021, Ostermann et al., 2020).

Choosing the optimal perioperative setting and delivery window

Elective cardiac surgery offers a comparatively tractable first clinical platform because risk can be assessed, pharmacokinetic sampling can begin before an anticipated insult, and postoperative endpoints can be obtained in a standardized manner. Even so, fasting and formulation-dependent absorption can make oral delivery unreliable. A preoperative pilot study could determine whether an acceptable formulation produces reproducible γ-tocotrienol concentrations under realistic fasting and medication schedules. The objective would be feasibility and exposure characterization, not efficacy claims. Emergency vascular surgery would generally be a poor initial model for preconditioning, although rescue treatment after reperfusion could later be considered if experimental timing studies support it. Transplantation presents alternative donor, recipient, and ex vivo routes that should not be conflated (Kamla et al., 2025, Oosterom-Eijmael et al., 2026, Penev et al., 2024).

Ex vivo delivery is conceptually appealing because the graft may be exposed under monitored conditions without relying on gastrointestinal absorption. However, many lipid-soluble compounds are challenging to distribute uniformly within aqueous perfusion media, and binding to circuit surfaces or proteins may alter delivered dose. Transplantation research increasingly investigates mitochondrial preservation and organ perfusion, but exposure engineering matters as much as target plausibility. Before any graft perfusion application, investigators should demonstrate compound stability, solubility, reproducible organ uptake, absence of harmful perfusion changes, and lack of unintended recipient exposure. Machine perfusion is thus a potential experimental platform for controlled pharmacology, not evidence that adding γ-tocotrienol will improve graft function (Hosgood et al., 2023, Abou Taka et al., 2023, McCully et al., 2026).

A tiered translational roadmap

The first research tier should comprise independent replication of the mouse γ-tocotrienol ischemia study, blinded pathology, prespecified endpoints, and transparent reporting of mortality and exclusions. Replication should include both sexes, older animals, and models with relevant pre-existing renal impairment, since healthy young mice do not reproduce surgical patient heterogeneity. Experiments should compare purified γ-tocotrienol with vehicle, alpha-tocopherol, and composition-defined tocotrienol mixtures, using appropriate dose-response and time-window analyses. The aim is to establish whether mitochondrial and renal effects are reproducible, compound-specific, and robust when administration occurs at different intervals before or after reperfusion rather than under one optimized pretreatment condition (Nowak and Megyesi, 2021, Yao et al., 2024, Li et al., 2025).

Figure 2 translates this evidence hierarchy into a staged research program. Advancement to each successive stage should depend on reproducibility, formulation-standardized exposure, and explicit safety thresholds rather than on antioxidant biomarkers alone (Nowak and Megyesi, 2021, Sharif et al., 2023).




Figure 2: Suggested stages from animal replication to clinically meaningful effectiveness trials.

The model requires independent preclinical validation before human exposure studies. Early human studies must establish pharmacokinetics and tolerability of precisely defined γ-tocotrienol, with surgical bleeding and concomitant antiplatelet or anticoagulant treatment evaluated explicitly. Subsequent randomized trials should distinguish mechanistic surrogate changes from prevention of KDIGO-defined AKI and durable renal outcomes.

The second tier should test mechanisms and exposure. Investigators could employ renal tubular cells, precision-cut kidney slices, or organoid systems to measure respiratory-chain function, ATP content, mitochondrial membrane potential, fission-fusion balance, mitophagy flux, and markers of lipid peroxidation. These outcomes should be integrated with renal tissue and plasma pharmacokinetics, including free and total compound, metabolites, and time-dependent exposure. Mechanistic perturbations addressing AMPK, mitochondrial DNA integrity, or quality-control pathways would help distinguish direct protection from nonspecific survival effects. Importantly, a successful high-dose cell-culture experiment should not determine the human dose, effective tissue concentrations must be compared with levels achievable using an acceptably safe clinical formulation (Ma et al., 2022, Su et al., 2023, Perico et al., 2024).

The third tier should be an early-phase human pharmacokinetic and safety program before any powered prevention trial. It would evaluate a chemically defined intervention under fed and fasting conditions relevant to perioperative practice, characterize peak exposure and elimination, and assess variability attributable to age, organ function, and concomitant medication. Surgery-associated bleeding and thrombotic endpoints should receive careful monitoring, particularly in groups requiring anticoagulants or antiplatelet drugs. Investigators should also verify adherence, exposure consistency, adverse effects, and relevant drug interactions. If predictable renal exposure cannot be achieved without excessive dose or formulation risks, clinical development should pause rather than rely on the credibility of the original mouse result (Sharif et al., 2023, Lee et al., 2022, Ooi et al., 2026).

The fourth tier could involve a randomized, double-blind, placebo-controlled pilot in a selected elective cardiac surgery population receiving standard kidney-protective care. A feasible design would measure serial creatinine and urine output, perioperative urinary [TIMP-2] × [IGFBP7] and NGAL where available, and exploratory injury or mitochondrial biomarkers. It should predefine how renal replacement therapy, sustained stage 2–3 AKI, and postdischarge kidney recovery will be evaluated. Importantly, an early biomarker study should primarily establish safety, pharmacokinetics, and proof of biological engagement rather than being marketed as a positive AKI prevention trial based solely on exploratory signals. A later multicenter efficacy study would require an independently estimated sample size and event rate (Irqsusi et al., 2022, Vandenberghe et al., 2023, Perez et al., 2025).

The fifth tier should evaluate patient-centered endpoints, including severe or persistent AKI, clinically indicated kidney replacement therapy, length of stay, renal recovery, and longer-term kidney function. Treatment effects on dialysis use must be interpreted with awareness that clinical thresholds and timing practices vary, a decision to start therapy is not purely a biomarker readout. The large STARRT-AKI trial illustrates that changing treatment timing does not necessarily produce survival benefit and may alter exposure to therapy-related harms. A translational framework should therefore avoid selecting endpoints solely because they are easy to measure or likely to produce a favorable statistical comparison. The strongest clinical evidence would demonstrate consistent benefit across mechanistic, kidney-organ, and patient-oriented levels (STARRT-AKI Investigators, 2020, Wang et al., 2023, Brown et al., 2023a).

Risk stratification, effect modification, and equitable trial design

Recent appraisals also stress that urinary injury and stress biomarkers do not necessarily identify a uniform biological subphenotype across operations or patient groups. In biomarker-enriched trial designs, prespecified timing, assay platform, threshold, kidney-function baseline, and the distinction between damage and stress signals are therefore essential. Such design choices can improve interpretability without implying that biomarker enrichment establishes an intervention's therapeutic mechanism (Zuzda et al., 2026, Douville et al., 2025).

Surgical AKI is heterogeneous. Baseline estimated glomerular filtration rate, diabetes, age, sex, cardiac dysfunction, anemia, major vessel disease, chronic inflammation, and nephrotoxin exposure may modify both the probability of injury and the response to an intervention. An enriched trial could improve efficiency by enrolling patients with elevated clinical risk or validated biomarker evidence of tubular stress. Nevertheless, enrichment may limit generalizability, and prespecified interactions must be handled conservatively. Pharmacological exposure may also vary among subgroups because lipid absorption and distribution depend on comorbidities and medication regimens. Rather than assuming a uniform antioxidant effect, developers should collect sufficiently detailed physiological and pharmacological data to understand why some patients might respond while others do not (Kulthinee et al., 2024, Kamla et al., 2025, Scurt et al., 2024).

Figure 3 illustrates an indicative perioperative assessment schedule in which baseline susceptibility, operative exposures, early kidney-injury biomarkers, and recovery outcomes are measured in temporal sequence. The suggested time windows are methodological examples rather than validated γ-tocotrienol sampling schedules (Ostermann et al., 2020, Perez et al., 2025).




Figure 3: Illustrative trial timeline linking exposure, injury signals, and longer-term recovery.

Baseline kidney function and medication history are needed to interpret postoperative biomarkers and safety. Operative information helps characterize competing injury exposures, whereas early creatinine and urine-output measurements support the prespecified clinical AKI definition. Later assessments of kidney function, renal replacement therapy, and adverse events reveal whether an early laboratory signal translates into an outcome important to patients.

Designing future trials also requires caution about cointerventions. Standard operating procedures for cardiopulmonary bypass, perfusion oxygen delivery, hemodynamic targets, fluid management, and postoperative kidney bundles should be characterized because differences across centers can obscure or exaggerate apparent efficacy. Recent randomized data show that procedure-specific renal support interventions may yield detectable benefits, these must be balanced and documented in both arms. A new compound could also show no incremental effect if conventional care has already prevented the addressable fraction of injury. Such a result would not necessarily refute every biochemical mechanism, but it would matter decisively for clinical utility. The clinically important question is whether γ-tocotrienol adds meaningful value to good current care (Mukaida et al., 2023, Landoni et al., 2024, Losiggio et al., 2025).

Ethical, regulatory, and epistemic safeguards

The status of γ-tocotrienol as a food-derived compound does not eliminate the need for rigorous medicinal-product standards if it is tested to prevent postoperative organ injury. Investigators must assess product identity, manufacturing quality, dose consistency, toxicology, interactions, bleeding risk, and conditions for pausing administration. Clinical trials should use independent ethical review, transparent consent, prospective registration, prespecified outcomes, and adverse-event monitoring. Patients should not be encouraged to self-initiate high-dose tocotrienols before surgery, particularly when anticoagulation or anesthesia is planned. Scientific communication must likewise separate outcomes observed in rodents from outcomes established in surgical patients. Overstating readiness would risk both patient safety and the credibility of legitimate translational research (Jacob and Leaf, 2025, Thielmann et al., 2021, Ostermann et al., 2020).

Another safeguard is to acknowledge uncertainty in the meaning of recovery. A return of serum creatinine to baseline may coexist with ongoing tubular stress or maladaptive repair, and some biomarkers capture cellular responses rather than loss of filtration. Mitochondrial recovery itself may be spatially heterogeneous within the kidney, with distinct responses in proximal tubules, endothelium, and immune cells. Future development should account for these compartments and use longitudinal follow-up rather than measuring a single postoperative laboratory value. This is particularly relevant for transplantation, where immunological injury and graft preservation interact, and for major cardiovascular surgery, where ongoing cardiac dysfunction can alter filtration independently of intrinsic tubular injury (Fogo and Harris, 2025, Hinze et al., 2024, Lee et al., 2024).

A calibrated interpretation of the current evidence

The most defensible present interpretation has three levels. At the biochemical level, γ-tocotrienol has properties and laboratory findings compatible with modulation of oxidative and bioenergetic stress. At the animal-organ level, a specific pretreated mouse ischemia model showed preservation of respiratory activity and indicators of renal recovery. At the human surgical level, controlled evidence directly testing γ-tocotrienol for prevention of perioperative AKI remains insufficient. The distinction is not merely semantic: each transition adds uncertainty concerning dose, timing, pharmacokinetics, operative exposures, heterogeneity, safety, and outcomes. The original contribution of a responsible qualitative review is to organize these uncertainties into testable steps rather than to erase them with an undifferentiated claim of renoprotection (Nowak and Megyesi, 2021, Pan and Zhu, 2026, Zainal et al., 2022).

Conclusion and Future Directions

Palm-derived γ-tocotrienol is a scientifically interesting candidate for investigation in renal ischemia-reperfusion injury, largely because animal findings link pretreatment to preservation of mitochondrial respiration, energy status, tubular morphology, and indices of renal function. These findings establish a focused mechanistic rationale but not a perioperative treatment recommendation. Surgical AKI reflects interacting perfusion, inflammatory, mitochondrial, and epithelial processes, and a protective signal in one mouse model cannot be presumed to extend to cardiac surgery, vascular intervention, or kidney transplantation. Maintaining the distinction between mechanistic plausibility and clinical benefit is essential for responsible scientific translation.

Priority should be given to independent experimental replication, compound- and dose-specific mechanistic studies, pharmacokinetic characterization with a standardized formulation, and perioperative safety evaluation. Only if these requirements are met should researchers consider a carefully controlled proof-of-concept clinical study with biomarker, kidney-function, and patient-

centered outcomes. γ-Tocotrienol should be investigated as a potential complement to established renal-protective measures, not as a replacement for optimal perfusion, avoidance of nephrotoxins, individualized fluid management, and postoperative kidney monitoring. At present, clinical prevention of perioperative AKI with γ-tocotrienol remains an unproven hypothesis.

References

1. Abou Taka, M., Dugbartey, G.J. and Sener, A. (2023) The optimization of renal graft preservation temperature to mitigate cold ischemia-reperfusion injury in kidney transplantation, International Journal of Molecular Sciences, 24(1), 567. https://doi.org/10.3390/ijms24010567.
2. Barbosa, A.C.S. et al. (2023) Delayed graft function post renal transplantation: a review on animal models and therapeutics, American Journal of Physiology-Renal Physiology, 325(6), pp.F817–F825. https://doi.org/10.1152/ajprenal.00146.2023.
3. Brown, J.K. et al. (2023a) Adult cardiac surgery-associated acute kidney injury: joint consensus report, Journal of Cardiothoracic and Vascular Anesthesia, 37(9), pp.1579–1590. https://doi.org/10.1053/j.jvca.2023.05.032.
4. Brown, J.R. et al. (2023b) The Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists/American Society of Extracorporeal Technology clinical practice guidelines for the prevention of adult cardiac surgery-associated acute kidney injury, Annals of Thoracic Surgery, 115(1), pp. 34–42. https://doi.org/10.1016/j.athoracsur.2022.06.054.
5. Douville, N.J. et al. (2025) Perioperative acute kidney injury: diagnosis, prediction, prevention, and treatment, Anesthesiology, 142(1), pp. 180–201. https://doi.org/10.1097/ALN.0000000000005215.
6. Fogo, A.B. and Harris, R.C. (2025) Crosstalk between glomeruli and tubules, Nature Reviews Nephrology, 21, pp.189–199. https://doi.org/10.1038/s41581-024-00907-0.
7. Hasjim, B.J. et al. (2024) Perfusion techniques in kidney allograft preservation to reduce ischemic reperfusion injury: a systematic review and meta-analysis, Antioxidants, 13(6), 642. https://doi.org/10.3390/antiox13060642.
8. Hinze, C. et al. (2024) Epithelial cell states associated with kidney and allograft injury, Nature Reviews Nephrology, 20, pp.447–459. https://doi.org/10.1038/s41581-024-00834-0.
9. Hosgood, S.A. et al. (2023) Normothermic machine perfusion versus static cold storage in donation after circulatory death kidney transplantation: a randomized controlled trial, Nature Medicine, 29, pp.1511–1519. https://doi.org/10.1038/s41591-023-02376-7.
10. Ide, S. et al. (2021) Ferroptotic stress promotes the accumulation of pro-inflammatory proximal tubular cells in maladaptive renal repair, eLife, 10, e68603. https://doi.org/10.7554/eLife.68603.
11. Irqsusi, M. et al. (2022) Urinary TIMP-2 and IGFBP-7 protein levels as early predictors of acute kidney injury after cardiac surgery, Journal of Cardiac Surgery, 37, pp.717–724. https://doi.org/10.1111/jocs.16200.
12. Jacob, K.A. and Leaf, D.E. (2025) Cardiac surgery-associated acute kidney injury: an updated review of current preventive strategies, Anesthesiology Clinics, 43(2), pp.323–356. https://doi.org/10.1016/j.anclin.2025.01.001.
13. Kamla, C.-E., Meersch-Dini, M. and Palma, L.M.P. (2025) Kidney injury following cardiac surgery: a review of our current understanding, American Journal of Cardiovascular Drugs, 25, pp.337–348. https://doi.org/10.1007/s40256-024-00715-8.
14. Kulthinee, S. et al. (2024) Cardiac surgery-associated acute kidney injury in cardiopulmonary bypass: a focus on sex differences and preventive strategies, American Journal of Physiology-Renal Physiology, 327(6), pp.F994–F1004. https://doi.org/10.1152/ajprenal.00106.2024.
15. Landoni, G. et al. (2024) A randomized trial of intravenous amino acids for kidney protection, New England Journal of Medicine, 391(8), pp.687–698. https://doi.org/10.1056/NEJMoa2403769.
16. Lee, K., Jang, H.R. and Rabb, H. (2024) Lymphocytes and innate immune cells in acute kidney injury and repair, Nature Reviews Nephrology, 20, pp.789–805. https://doi.org/10.1038/s41581-024-00875-5.
17. Lee, Y.Z. et al. (2022) Formulation of oily tocotrienols as a solid self-emulsifying dosage form for improved oral bioavailability in human subjects, Journal of Drug Delivery Science and Technology, 76, 103752. https://doi.org/10.1016/j.jddst.2022.103752.
18. Li, H. et al. (2025) Advances in understanding the role of mitochondria in renal ischemia–reperfusion injury, Clinical and Experimental Nephrology, 29, pp.1685–1698. https://doi.org/10.1007/s10157-025-02727-3.
19. Losiggio, R. et al. (2025) Intravenous amino-acid infusion to prevent acute kidney injury after cardiac surgery: a review of the evidence, Annals of Thoracic Surgery, 120(2), pp.256–266. https://doi.org/10.1016/j.athoracsur.2024.11.020.
20. Ma, H. et al. (2022) Dephosphorylation of AMP-activated protein kinase exacerbates ischemia/reperfusion-induced acute kidney injury via mitochondrial dysfunction, Kidney International, 101(2), pp.315–330. https://doi.org/10.1016/j.kint.2021.10.028.
21. Ma, L. et al. (2023) Paeoniflorin alleviates ischemia/reperfusion induced acute kidney injury by inhibiting Slc7a11-mediated ferroptosis, International Immunopharmacology, 116, 109754. https://doi.org/10.1016/j.intimp.2023.109754.
22. Ma, N. et al. (2024) CHOP-mediated Gasdermin E expression promotes pyroptosis, inflammation, and mitochondrial damage in renal ischemia-reperfusion injury, Cell Death & Disease, 15, 163. https://doi.org/10.1038/s41419-024-06525-9.
23. Malinoski, D. et al. (2023) Hypothermia or machine perfusion in kidney donors, New England Journal of Medicine, 388, pp.418–426. https://doi.org/10.1056/NEJMoa2118265.
24. McCully, J.D. et al. (2026) Therapeutic and mechanistic insights on mitochondrial transplantation in kidney disease, Nature Reviews Nephrology, 22, pp.459–473. https://doi.org/10.1038/s41581-026-01072-2.
25. Meng, X.-M. et al. (2025) Innate immune cells in acute and chronic kidney disease, Nature Reviews Nephrology, 21, pp.464–482. https://doi.org/10.1038/s41581-025-00958-x.
26. Mohamad, N.-V. (2023) Strategies to enhance the solubility and bioavailability of tocotrienols using self-emulsifying drug delivery system, Pharmaceuticals, 16(10), 1403. https://doi.org/10.3390/ph16101403.
27. Mukaida, H. et al. (2023) Oxygen delivery-guided perfusion for the prevention of acute kidney injury: a randomized controlled trial, Journal of Thoracic and Cardiovascular Surgery, 165(2), pp.750–760.e5. https://doi.org/10.1016/j.jtcvs.2021.03.032.
28. Ng, C. et al. (2025) Oxidative stress and NRF2 signaling in kidney injury, Toxicological Research, 41(2), pp.131–147. https://doi.org/10.1007/s43188-024-00272-x.
29. Nowak, G. and Megyesi, J. (2021) γ-Tocotrienol protects against mitochondrial dysfunction, energy deficits, morphological damage, and decreases in renal functions after renal ischemia, International Journal of Molecular Sciences, 22(23), 12674. https://doi.org/10.3390/ijms222312674.
30. Ooi, A.G. et al. (2026) Oral delivery of tocotrienols: addressing pharmacokinetic challenges with formulation-based strategies, Lipids, advance online publication. https://doi.org/10.1002/lipd.70069.

31. Oosterom-Eijmael, M.J.P. et al. (2026) Cardiac surgery-associated acute kidney injury, BJA Education, 26(2), pp.92–100. https://doi.org/10.1016/j.bjae.2025.11.001.
32. Ostermann, M. et al. (2020) Recommendations on acute kidney injury biomarkers from the Acute Disease Quality Initiative consensus conference: a consensus statement, JAMA Network Open, 3(10), e2019209. https://doi.org/10.1001/jamanetworkopen.2020.19209.
33. Pabla, N. and Bajwa, A. (2022) Ischemic reperfusion injury and AKI: role for mitochondrial therapy, Nephron, 146(3), pp.253–258. https://doi.org/10.1159/000520698.
34. Pan, J. et al. (2023) Inhibition of USP14 suppresses ROS-dependent ferroptosis and alleviates renal ischemia/reperfusion injury, Cell Biochemistry and Biophysics, 81(1), pp.87–96. https://doi.org/10.1007/s12013-022-01107-y.
35. Pan, Y. and Zhu, J. (2026) Mitochondria in renal ischemia–reperfusion injury: from mechanisms to therapeutics, Biomedicines, 14(2), 310. https://doi.org/10.3390/biomedicines14020310.
36. Penev, Y. et al. (2024) Intraoperative hypotension and postoperative acute kidney injury: a systematic review, American Journal of Surgery, 232, pp.45–53. https://doi.org/10.1016/j.amjsurg.2024.02.001.
37. Perez, S.C. et al. (2025) Biomarkers of postoperative cardiac surgery-associated acute kidney injury: narrowing the field, JTCVS Open, 25, pp.264–274. https://doi.org/10.1016/j.xjon.2025.03.021
38. Perico, L., Remuzzi, G. and Benigni, A. (2024) Sirtuins in kidney health and disease, Nature Reviews Nephrology, 20, pp.313–329. https://doi.org/10.1038/s41581-024-00806-4.
39. Ponticelli, C., Reggiani, F. and Moroni, G. (2022) Delayed graft function in kidney transplant: risk factors, consequences and prevention strategies, Journal of Personalized Medicine, 12(10), 1557. https://doi.org/10.3390/jpm12101557.
40. Prowle, J.R. et al. (2021) Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative, Nature Reviews Nephrology, 17, pp.605–618. https://doi.org/10.1038/s41581-021-00418-2.
41. Ranasinghe, R. et al. (2022) Revisiting the therapeutic potential of tocotrienol, BioFactors, 48(4), pp.813–856. https://doi.org/10.1002/biof.1873.
42. Scurt, F.G. et al. (2024) Cardiac surgery-associated acute kidney injury, Kidney360, 5(6), pp.909–926. https://doi.org/10.34067/KID.0000000000000466.
43. Sharif, M. et al. (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review, Journal of Pakistan Medical Association, 73(3), pp.603–610. https://doi.org/10.47391/JPMA.6008.
44. STARRT-AKI Investigators (2020) Timing of initiation of renal-replacement therapy in acute kidney injury, New England Journal of Medicine, 383(3), pp.240–251. https://doi.org/10.1056/NEJMoa2000741.
45. Su, L. et al. (2023) Mitochondria ROS and mitophagy in acute kidney injury, Autophagy, 19(2), pp.401–414. https://doi.org/10.1080/15548627.2022.2084862.
46. Szewczyk, K., Chojnacka, A. and Górnicka, M. (2021) Tocopherols and tocotrienols—bioactive dietary compounds, what is certain, what is doubt?, International Journal of Molecular Sciences, 22(12), 6222. https://doi.org/10.3390/ijms22126222.
47. Tang, C. et al. (2021) Mitochondrial quality control in kidney injury and repair, Nature Reviews Nephrology, 17, pp.299–318. https://doi.org/10.1038/s41581-020-00369-0.
48. Thapa, K., Singh, T.G. and Kaur, A. (2022) Targeting ferroptosis in ischemia/reperfusion renal injury, Naunyn-Schmiedebergs Archives of Pharmacology, 395, pp.1331–1341. https://doi.org/10.1007/s00210-022-02277-5.
49. Thielmann, M. et al. (2021) Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study, Circulation, 144(14), pp.1133–1144. https://doi.org/10.1161/CIRCULATIONAHA.120.053029.
50. Vandenberghe, W. et al. (2023) Potential of urine biomarkers CHI3L1, NGAL, TIMP-2, IGFBP7, and combinations as complementary diagnostic tools for acute kidney injury after pediatric cardiac surgery: a prospective cohort study, Diagnostics, 13(6), 1047. https://doi.org/10.3390/diagnostics13061047.
51. Wang, W., Shen, Q. and Zhou, X. (2023) The predictive value of [TIMP-2]*[IGFBP7] in adverse outcomes for acute kidney injury: a systematic review and meta-analysis, Renal Failure, 45. https://doi.org/10.1080/0886022X.2023.2253933.
52. Wang, Y. et al. (2020) Mitophagy in acute kidney injury and kidney repair, Cells, 9(2), 338. https://doi.org/10.3390/cells9020338.
53. Yao, C. et al. (2024) Mitochondrial dysfunction in acute kidney injury, Renal Failure, 46(2), 2393262. https://doi.org/10.1080/0886022X.2024.2393262.
54. Zainal, Z. et al. (2022) Therapeutic potential of palm oil vitamin E-derived tocotrienols in inflammation and chronic diseases: evidence from preclinical and clinical studies, Food Research International, 156, 111175. https://doi.org/10.1016/j.foodres.2022.111175
55. Zarbock, A. et al. (2021) Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: the PrevAKI-multicenter randomized controlled trial, Anesthesia & Analgesia, 133(2), pp.292–302. https://doi.org/10.1213/ANE.0000000000005458.
56. Zhao, M. et al. (2021) Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance, Theranostics, 11(4), pp.1845–1863. https://doi.org/10.7150/thno.50905.
57. Zhuang, S. et al. (2021) Targeting P2RX1 alleviates renal ischemia/reperfusion injury by preserving mitochondrial dynamics, Pharmacological Research, 170, 105712. https://doi.org/10.1016/j.phrs.2021.105712.
58. Zuzda, K., Walczak-Wieteska, P., Andruszkiewicz, P. and Małyszko, J. (2026) Acute kidney injury biomarkers in perioperative care: a scoping review of clinical implementation, Diagnostics, 16(1), 94. https://doi.org/10.3390/diagnostics16010094.

Copyright: © 2026 Loso Judijanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.